IP Library Granted Patent US 8,173,656
Granted Patent B2
US 8,173,656 · App. 12/970,659 · Granted May 8, 2012

Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Assignee: Janssen Pharmaceutica NV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,656
App. No.
12/970,659
Granted
May 8, 2012
Kind
B2
Abstract

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Claims (17)

1. A compound selected from

4-[5-(1H-Pyrazol-4-yl)-imidazo[1,2-a]pyrazin-8-ylamino]-cyclohexanol;

(1H-Indol-5-yl)-[5-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazin-8-yl]-amine; and

4-[8-(1H-Indol-5-ylamino)-imidazo[1,2-a]pyrazin-5-yl]-benzamide; and

pharmaceutically acceptable salts thereof.

2. A compound selected from (1H-Indol-5-yl)-[5-(1H-pyrazol-4-yl)-imidazo[1,2-a]pyrazin-8-yl]-amine; and

pharmaceutically acceptable salts thereof.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1 .

4. The pharmaceutical composition of claim 3 , wherein the carrier is a parenteral carrier.

5. The pharmaceutical composition of claim 3 , wherein the carrier is an oral carrier.

6. The pharmaceutical composition of claim 3 , wherein the carrier is a topical carrier.

7. A method of treatment of rheumatoid arthritis, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound according to claim 1 .

8. A method of treatment of rheumatoid arthritis, which comprises administering to a subject in need thereof, a therapeutically effective amount of a compound according to claim 2 .

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 2 .

10. The pharmaceutical composition of claim 9 , wherein the carrier is a parenteral carrier.

11. The pharmaceutical composition of claim 9 , wherein the carrier is an oral carrier.

12. The pharmaceutical composition of claim 9 , wherein the carrier is a topical carrier.

Continuity (7)
Division 11803015 · May 11, 2007
Provisional Application 60747223 · May 15, 2006
Provisional Application 60928539 · May 10, 2007
Provisional Application 60928600 · May 10, 2007
Provisional Application 60928639 · May 10, 2007
Provisional Application 60928568 · May 10, 2007
Related Publication 20110218178A1 · Sep 8, 2011